As noted elsewhere in this issue (see "The Lure of Late-Stage Device Investing," in this issue [A#2006900211]), 2006 has seen a marked uptick in large financings by late-stage device start-ups. Average amounts raised in Series C and later deals has climbed steadily to over $22 million from just under $15 million in 2003, and an unprecedented ten device firms have raised $30 million or more in single deals so far this year (see Exhibit 1).
VCs Turn to Late-Stage Devices
To date, 2006 has seen a marked uptick in large financings by late-stage device start-ups. Average amounts raised in Series C and later deals has climbed steadily to over $22 million from just under $15 million in 2003, and an unprecedented ten device firms have raised $30 million or more in single deals so far this year.
More from Strategy
• By
Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.
• By
Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."
• By
Medtech Insight sat down with Intuitive Surgical CEO Gary Guthart at the recent LSI USA conference to discuss the full launch of the new da Vinci 5 robotic system and planned digital enhancements. Guthart also offered his views on health care interoperability, AI regulation, outpatient surgeries, autonomous robots, and how the company is harnessing technology to shape the future of robotic surgery.
More from Business
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
Leann Sims joins AbundaBox as COO; Oura Ring firm appoints CMO.
• By
Vektor Medical is ramping up efforts to bring its vMap technology used to identify arrhythmia sources to more US hospitals, start enrollment in a multinational trial, and commercialize in Europe, pending the CE mark. Medtech Insight sat down with CEO Rob Krummen at LSI 2025 to discuss their plans.